The androgen receptor has no direct antiresorptive actions in mouse osteoclasts

Mieke Sinnesael1, Ferran Jardi1, Ludo Deboel1

  • 1Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium.

Insights

Androgen receptor (AR) does not directly suppress bone resorption in osteoclasts. Bone marrow stromal cells (BMSCs) appear to mediate AR

Area of Science:

  • Bone Biology
  • Endocrinology
  • Cell Biology

Background:

  • Androgen deficiency causes high-turnover osteopenia, but the specific cells mediating this effect are unknown.
  • The role of the androgen receptor (AR) in regulating bone resorption requires clarification.

Purpose of the Study:

  • To determine if AR in osteoclasts directly suppresses bone resorption.
  • To investigate the cellular targets of AR in bone metabolism.

Main Methods:

  • Generated osteoclast-specific AR knockout (ocl-ARKO) mice by crossing AR-floxed with cathepsin K-Cre mice.
  • Utilized cell cultures from ubiquitous ARKO and wild-type mice, including bone marrow stromal cells (BMSCs) and osteoblasts.
  • Performed co-culture experiments and analyzed gene expression of key bone remodeling markers (Rankl, Opg, Runx2).

Main Results:

  • Osteoclast-specific ARKO mice showed no alterations in bone microarchitecture or resorption.
  • AR levels were minimal in osteoclasts, suggesting a limited direct role.
  • In co-cultures, AR signaling in BMSCs was crucial for suppressing osteoclastogenesis and activity.
  • AR deficiency in BMSCs altered the Rankl/Opg ratio and increased Runx2 expression, favoring osteoblastogenesis.

Conclusions:

  • The androgen receptor does not directly inhibit bone resorption via osteoclasts.
  • Bone marrow stromal cells are likely key mediators of AR's suppressive effects on bone resorption.
  • AR signaling in BMSCs influences the balance between osteoblast and osteoclast differentiation.